Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy By Ogkologos - February 19, 2026 193 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the marginal zone lymphoma cohort of the TRANSCEND FL study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer October 31, 2019 From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... September 13, 2024 Can Immunotherapy Succeed in Glioblastoma? May 24, 2018 Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... July 1, 2024 Load more HOT NEWS Women in science: Cancer research pioneers – part 2 Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... Living With Metastatic Breast Cancer: How I Reinvented Myself Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival...
